MDxHealth Completes Migration to Nasdaq Single Listing, Exits Euronext Brussels

GateUser-a5fa8bd0 · 2025-12-31T10:19:43+00:00

MDxHealth has completed its delisting from Euronext Brussels as of December 18, 2023, consolidating its stock exclusively on Nasdaq. Shareholders retain ownership rights and can reposition shares not migrated by the deadline. The company specializes in precision diagnostics for urologic cancer.

GateUser-a5fa8bd0

2025-12-31 10:19:43

Abstract generation in progress

MDxHealth, a precision diagnostics innovator operating in the urologic cancer diagnostics space, has finalized its delisting from Euronext Brussels as of December 18, 2023. The company now maintains exclusive listing status on Nasdaq following the conclusion of its transition strategy announced earlier in the year.

Delisting Timeline and Market Impact

The last trading session for MDxHealth shares on Euronext Brussels occurred on December 15, 2023, marking the end of the company’s dual-listing arrangement. Starting December 18, 2023, securities are no longer available for trading on the Belgian exchange and have consolidated exclusively on Nasdaq under the ticker MDXH. This shift represents a strategic consolidation aimed at streamlining the company’s capital market presence and improving trading accessibility for its investor base.

Shareholder Repositioning and Share Validity

All existing shareholders retain full ownership rights regardless of whether their shares have been repositioned to Nasdaq. The company emphasized that share repositioning remains available for shareholders who did not complete the migration by the December 15 deadline. Investors holding shares on the Euronext platform can contact their financial intermediaries or custodians to facilitate repositioning on mdxhealth’s Nasdaq exchange listing at any time following the transition date.

About MDxHealth’s Operations

MDxHealth operates as a commercial-stage precision diagnostics provider specializing in molecular-based testing for urologic conditions. The company’s diagnostic solutions leverage proprietary genomic and epigenetic technologies to deliver actionable insights for clinical decision-making. U.S. laboratory facilities are headquartered in Irvine, California, with additional capacity in Plano, Texas. European operations are centered in Herstal, Belgium, supplemented by laboratory infrastructure in Nijmegen, The Netherlands.

Forward-Looking Considerations

The company’s transition to a Nasdaq-exclusive listing follows standard corporate restructuring protocols. MDxHealth notes that various factors—including market conditions, regulatory developments, and competitive dynamics—may influence future performance. Interested parties can access comprehensive information regarding the listing transition through mdxhealth’s investor relations portal.

For investor inquiries: ir@mdxhealth.com | US: +1 949 271 9223

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.